
Ireena Vittal joins Cipla executive board
pharmafile | November 29, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cipla, appointment
Indian drug maker Cipla has expanded its board with the addition of Ireena Vittal as an independent director, effective 1 December, 2016.
A former partner with consultant McKinsey & Company, Vittal is considered a thought leader for consumer-facing businesses in emerging markets and brings over two decades of business and management expertise to the role. In her previous roles, she has served tenures at Nestle, MaxTouch (now Vodafone) and a number of government and public development schemes.
Cipla non-executive chairman Y K Hamied remarked: “We are delighted to welcome Vittal to our Board. Cipla is in the midst of preparing itself for an exciting future and her background of both business and advisory will be very useful to the company.”
Vittal herself commented: “I am honoured to have been invited to join the Board of one of India’s most respected and iconic companies. These are very exciting times for Cipla as it transforms itself to be even more relevant to the millions of patients globally.”
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …






